• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Educational case: Estrogen-receptor positive breast cancer: Diagnosis, response to therapy, and prognosis.

作者信息

Afifi Ahmed, Hammer Phoebe, Ernst Kelly

机构信息

Benha University Faculty of Medicine, Benha, Al-Qalyubia Governorate, Egypt.

Stanford University, Palo Alto, CA, USA.

出版信息

Acad Pathol. 2025 Aug 12;12(3):100210. doi: 10.1016/j.acpath.2025.100210. eCollection 2025 Jul-Sep.

DOI:10.1016/j.acpath.2025.100210
PMID:40831739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12359217/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/1a3c7ed15571/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/45bcd34703a3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/3b0b406eede3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/3b9f67509631/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/70ef6d350da0/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/1a3c7ed15571/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/45bcd34703a3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/3b0b406eede3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/3b9f67509631/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/70ef6d350da0/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46da/12359217/1a3c7ed15571/gr5.jpg

相似文献

1
Educational case: Estrogen-receptor positive breast cancer: Diagnosis, response to therapy, and prognosis.教学案例：雌激素受体阳性乳腺癌：诊断、治疗反应及预后
Acad Pathol. 2025 Aug 12;12(3):100210. doi: 10.1016/j.acpath.2025.100210. eCollection 2025 Jul-Sep.
2
Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.整合蛋白质组学和转录组学分析揭示雌激素受体阳性/孕激素受体阳性与雌激素受体阳性/孕激素受体阴性乳腺癌之间的关键调控基因。
BMC Cancer. 2025 Jul 1;25(1):1048. doi: 10.1186/s12885-025-14451-y.
3
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险：预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
4
Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.评估 Oncotype DX 复发评分作为雌激素受体阳性、淋巴结阴性的日本女性原发性Ⅰ期或ⅡA 期乳腺癌的预后因素。
J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.
5
Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types.用于鉴定与HER2阳性和三阴型乳腺癌相关的预后关键基因及重要通路的连贯数据分析
Sci Rep. 2025 Jul 2;15(1):23675. doi: 10.1038/s41598-025-94084-0.
6
Clinical significance of androgen receptor in unilateral invasive breast cancer in women.雄激素受体在女性单侧浸润性乳腺癌中的临床意义。
Eur J Med Res. 2025 Aug 23;30(1):793. doi: 10.1186/s40001-025-03072-7.
7
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.基因表达谱分析和扩展免疫组织化学检测在乳腺癌管理中指导辅助化疗的应用：系统评价和成本效益分析。
Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440.
8
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.早期乳腺癌患者 HER2-低表达的临床病理特征及预后意义：激素受体状态分层的 HER2-低表达与 HER2 阴性乳腺癌的预后比较。
Breast J. 2023 Nov 30;2023:6621409. doi: 10.1155/2023/6621409. eCollection 2023.
9
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.雌激素受体低表达和阴性早期乳腺癌的免疫及基因表达谱分析
J Natl Cancer Inst. 2024 Dec 1;116(12):1914-1927. doi: 10.1093/jnci/djae178.
10
Educational Case: HER-2 Positive Breast Cancer.教育案例：HER-2阳性乳腺癌
Acad Pathol. 2021 Sep 14;8:23742895211041737. doi: 10.1177/23742895211041737. eCollection 2021 Jan-Dec.

本文引用的文献

1
HER2-Low Breast Cancer: Current Landscape and Future Prospects.HER2低表达乳腺癌：现状与未来展望
Breast Cancer (Dove Med Press). 2023 Aug 14;15:605-616. doi: 10.2147/BCTT.S366122. eCollection 2023.
2
Pathology Competencies in Medical Education and Educational Cases: Update 2023.医学教育中的病理学能力与教育案例：2023年更新
Acad Pathol. 2023 Jul 12;10(3):100086. doi: 10.1016/j.acpath.2023.100086. eCollection 2023 Jul-Sep.
3
Breast Cancer Statistics, 2022.2022 年乳腺癌统计数据。
CA Cancer J Clin. 2022 Nov;72(6):524-541. doi: 10.3322/caac.21754. Epub 2022 Oct 3.
4
Determining breast cancer biomarker status and associated morphological features using deep learning.使用深度学习确定乳腺癌生物标志物状态及相关形态学特征。
Commun Med (Lond). 2021 Jul 14;1:14. doi: 10.1038/s43856-021-00013-3. eCollection 2021.
5
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.乳腺癌内分泌耐药：从分子机制到治疗策略。
J Mol Med (Berl). 2021 Dec;99(12):1691-1710. doi: 10.1007/s00109-021-02136-5. Epub 2021 Oct 8.
6
Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.乳腺癌——流行病学、危险因素、分类、预后标志物及当前治疗策略——最新综述
Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
7
Grading of invasive breast carcinoma: the way forward.浸润性乳腺癌分级：未来之路。
Virchows Arch. 2022 Jan;480(1):33-43. doi: 10.1007/s00428-021-03141-2. Epub 2021 Jul 1.
8
Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement.肿瘤大小对伴有广泛淋巴结受累的乳腺癌的预后仍有影响。
Front Oncol. 2021 Apr 9;11:585613. doi: 10.3389/fonc.2021.585613. eCollection 2021.
9
The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up.激素反应性乳腺癌中Ki-67的合适临界值：一项长期随访的单机构分析
Breast Cancer (Dove Med Press). 2021 Apr 7;13:213-217. doi: 10.2147/BCTT.S305440. eCollection 2021.
10
Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.雌激素阳性乳腺癌内分泌耐药的分子机制。
Front Endocrinol (Lausanne). 2021 Mar 25;12:599586. doi: 10.3389/fendo.2021.599586. eCollection 2021.